These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Five years follow-up of infections with extended-spectrum beta-lactamase producing enterobacteriaceae].
    Author: Fouquet M, Morange V, Bruyère F.
    Journal: Prog Urol; 2012 Jan; 22(1):17-21. PubMed ID: 22196001.
    Abstract:
    INTRODUCTION: Actually, epidemiology of extended-spectrum β-lactamase (ESBL) producing enterobacteriaceae is increasing worldwide, especially in urinary tract infections (UTI). The objective of the study was to investigate the epidemiology of ESBL producers in a department of urology. PATIENTS AND METHODS: This was a retrospective, monocentric study, which included all patients with positive culture showing an ESBL producing enterobacteriaceae in a department of urology between 2005 and 2009 included. RESULTS: The prevalence of ESBL producers in UTI was 2/113 (1.8%) in 2005 and 3/196 (1.5%) in 2009 (P=0.87). Twenty-seven isolates were included: 66.7% of Escherichia coli, 11.1% of Klebsiella pneumoniae, 11.1% of Enterobacter cloacae. ESBL producers were resistant to another antibiotic family in 24 cases (88.8%). The mean age in this study was 70.4 years, 70% of patients had another antibiotherapy in the past 6 months, 87% an hospitalization within 90% had surgery. Among the patients, 56.5% had a material. The infection was community-acquired in three cases only. Thirty-five percent of patients had no symptoms, 26% presented with severe sepsis. CONCLUSION: This report was a five-year retrospective study of BLSE-positive bacteria showing the nosocomial infection with ESBL producers and their multiresistance to usual antibiotics without any increase of their prevalence.
    [Abstract] [Full Text] [Related] [New Search]